pharmaceuticals

Shoppers deterred by terrorist attacks

Gold funds top performance charts

Winterflood's latest review

Crackdown on domicile changes

Biotech has fallen

The Merchants trust's Simon Gergel explains why investing in one of the UK's biggest healthcare stocks - GlaxoSmithKline - is not as simple as many investors envisage

Hardeep Tawakley takes a closer look at the evolution of specialist funds and speaks to buyers about their favourite offerings.

L&G and Glaxo under the microscope

Moore succeeds Mott on fund

Costs "unsustainable"